Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of posaconazole in children with invasive aspergillosis
MOH_2020-01-07_008598Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of posaconazole in invasive aspergillosis (IA), sponsored by Merck & Co. Primary endpoint: Safety of posaconazole. Started Nov 2019; status: active, not recruiting.
02
Drugs
posaconazole
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on MOH_2020-01-07_008598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-01-07_008598.